To cite this paper use one of the standards below:
Case presentation: A 29-year female was referred to our service after three recurrent episodes of partial transverse myelitis during one year. Multiple sclerosis (MS) was diagnosed based on compatible clinical, MRI and CSF data (Figure 1). She had no personal or family history of dermatologic or autoimmune diseases. Treatment with Natalizumab was indicated, and her first infusion had only a minor reaction (i.e., cervical pruritus). Few days after the second infusion, however, she developed painful crusted erythematous plaques and vesicles in both hands (Figure 2A). Biopsy revealed spongiotic dermatitis with acanthosis and perivascular infiltrates (Figure 2B). She improved completely after oral and topical corticosteroids. Lesions recurred on the fifth day after the third dose, this time involving all limbs and trunk. After case review with Dermatology, she started a course of prednisone 20 mg per day from two days before to three days after each infusion. Subsequent infusions, three so far, were carried out without lesion recurrence (Figure 2C). Discussion: Natalizumab has one of the safest profiles among high-efficacy disease-modifying therapies for MS. Although delayed allergic reactions are well recognized, other cutaneous abnormalities have been scarcely reported, as is the case of hyperkeratotic lesions (Table 1). Previous reports have raised a relationship between Natalizumab infusions and psoriasis development or worsening; an increase of peripheral CD4+IL17+ lymphocytes was postulated as a potential cause. Spongiotic dermatitis, in its turn, has been associated with Natalizumab in only one other case. Dysregulation of natural-killer cells by the drug was also proposed as a mechanism. Final Comments: This report is the second to describe a possible relationship between Natalizumab infusion and spongiotic dermatitis. Recognition of rare dermatologic complications of Natalizumab and their adequate management are important, especially considering its role in MS treatment and limitation of prompt access to other high-efficacy options.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper